13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773206
Total reported value
$2.5B
$2.5B
66 檔
12.4%
In Q3 2024, Integral Health Asset Management, LLC's U.S. equity holdings reached a combined market value of $2.5B, distributed across 66 disclosed stock positions.
Integral Health Asset Management, LLC executed strategic sector rebalancing during Q3 2024, establishing 31 new positions while fully exiting 34 holdings and trimming 15 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 11.91% | -4.99% | -6.45% | |
| 2 | THC | Tenet Healthcare CORP | Stock-Healthcare | 9.91% | +1.22% | NEW | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.19% | -0.13% | -15.38% | |
| 4 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.46% | -2.82% | -25.00% | |
| 5 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 3.94% | — | -4.55% | |
| 6 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 3.80% | +0.18% | NEW | |
| 7 | MDT | Medtronic plc | Stock-Healthcare | 3.04% | +0.62% | NEW | |
| 8 | 2655787D | Blueprint Medicines CORP | Stock-Other | 3.02% | — | -14.71% | |
| 9 | EHC | Encompass Health CORP | Stock-Healthcare | 2.99% | — | -8.33% | |
| 10 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 2.59% | -0.59% | -33.33% | |
| 11 | ACLXGBX | Arcellx Inc | Stock-Other | 2.58% | — | — | |
| 12 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.56% | -0.66% | -14.89% | |
| 13 | VERA | Vera Therapeutics Inc | Stock-Other | 2.49% | -0.11% | — | |
| 14 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 2.10% | +1.11% | +20.00% | |
| 15 | NARIUSD | Inari Medical Inc | Stock-Other | 1.86% | — | — | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.79% | +0.53% | +7.69% | |
| 17 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.78% | -0.39% | EXIT | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.72% | — | -25.00% | |
| 19 | RGNX | Regenxbio Inc | Stock-Other | 1.50% | -0.22% | +34.21% | |
| 20 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.50% | +0.80% | — | |
| 21 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.39% | -0.67% | EXIT | |
| 22 | COO | Cooper Cos Inc/the | Stock-Healthcare | 1.37% | -0.51% | EXIT | |
| 23 | KROS | Keros Therapeutics Inc | Stock-Other | 1.31% | — | +135.29% | |
| 24 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.25% | — | — | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.15% | +0.15% | NEW | |
| 26 | FMS | Fresenius Medical Care-adr | Stock-Other | 1.08% | -0.84% | EXIT | |
| 27 | BRKR | Bruker CORP | Stock-Healthcare | 1.05% | +0.36% | NEW | |
| 28 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.02% | — | — | |
| 29 | LLY | Eli Lilly & Co | Stock-Healthcare | 1.00% | +0.05% | — | |
| 30 | DXCM | Dexcom Inc | Stock-Healthcare | 0.91% | -0.53% | EXIT | |
| 31 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.89% | — | +45.45% | |
| 32 | SANA | Sana Biotechnology Inc | Stock-Other | 0.84% | -0.16% | +50.00% | |
| 33 | TFX | Teleflex Inc | Stock-Healthcare | 0.83% | — | -33.33% | |
| 34 | BTSG | Brightspring Health Services | Stock-Other | 0.83% | -1.03% | — | |
| 35 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.79% | — | — | |
| 36 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.77% | — | — | |
| 37 | APLT | Applied Therapeutics Inc | Stock-Other | 0.77% | — | — | |
| 38 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.74% | — | — | |
| 39 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 0.72% | — | — | |
| 40 | BNTX | Biontech Se-adr | Stock-Other | 0.67% | +0.18% | NEW | |
| 41 | QDEL | Quidelortho CORP | Stock-Other | 0.64% | — | -16.67% | |
| 42 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.64% | — | — | |
| 43 | EVH | Evolent Health Inc - A | Stock-Other | 0.64% | — | — | |
| 44 | EXK | Exact Sciences CORP | Stock-Materials | 0.61% | — | — | |
| 45 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 0.53% | -0.29% | EXIT | |
| 46 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.52% | — | +2.15% | |
| 47 | TWST | Twist Bioscience CORP | Stock-Other | 0.51% | — | — | |
| 48 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.51% | -0.52% | EXIT | |
| 49 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.49% | -1.14% | — | |
| 50 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.46% | — | -43.66% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSP | Inspire Medical Systems Inc | +3.8% | NEW | New buy |
| 2 | THC | Tenet Healthcare CORP | +3.6% | +6.00% | Add |
| 3 | MDT | Medtronic plc | +3% | NEW | New buy |
| 4 | INSM | Insmed Inc | +2% | -6.45% | Trim |
| 5 | EWTX | Edgewise Therapeutics Inc | +1.5% | NEW | New buy |
| 6 | COO | Cooper Cos Inc/the | +1.4% | NEW | New buy |
| 7 | CLDX | Celldex Therapeutics Inc | +1.2% | NEW | New buy |
| 8 | ACLXGBX | Arcellx Inc | +1.1% | — | Unchanged |
| 9 | ✓ | Longboard Pharmaceuticals In | +1.1% | -4.55% | Trim |
| 10 | FMS | Fresenius Medical Care-adr | +1.1% | NEW | New buy |
| 11 | BMY | Bristol-myers Squibb Co | +1% | NEW | New buy |
| 12 | KROS | Keros Therapeutics Inc | +0.9% | +135.29% | Add |
| 13 | DXCM | Dexcom Inc | +0.9% | NEW | New buy |
| 14 | BTSG | Brightspring Health Services | +0.8% | NEW | New buy |
| 15 | DGX | Quest Diagnostics Inc | +0.8% | +20.00% | Add |
| 16 | ALNY | Alnylam Pharmaceuticals Inc | +0.8% | NEW | New buy |
| 17 | APLT | Applied Therapeutics Inc | +0.8% | NEW | New buy |
| 18 | VERA | Vera Therapeutics Inc | +0.8% | — | Unchanged |
| 19 | JSPR | Jasper Therapeutics Inc | +0.7% | NEW | New buy |
| 20 | TNDM | Tandem Diabetes Care Inc | +0.7% | NEW | New buy |
| 21 | BNTX | Biontech Se-adr | +0.7% | NEW | New buy |
| 22 | VRDN | Viridian Therapeutics Inc | +0.6% | NEW | New buy |
| 23 | EVH | Evolent Health Inc - A | +0.6% | NEW | New buy |
| 24 | EXK | Exact Sciences CORP | +0.6% | NEW | New buy |
| 25 | RVMD | Revolution Medicines Inc | +0.6% | +7.69% | Add |
| 26 | EHC | Encompass Health CORP | +0.6% | -8.33% | Trim |
| 27 | IQV | Iqvia Holdings Inc | +0.5% | NEW | New buy |
| 28 | TWST | Twist Bioscience CORP | +0.5% | NEW | New buy |
| 29 | MLYS | Mineralys Therapeutics Inc | +0.5% | NEW | New buy |
| 30 | CPRX | Catalyst Pharmaceuticals Inc | +0.5% | +45.45% | Add |
| 31 | RGNX | Regenxbio Inc | +0.4% | +34.21% | Add |
| 32 | BSX | Boston Scientific CORP | +0.4% | -15.38% | Trim |
| 33 | RVTY | Revvity Inc | +0.4% | NEW | New buy |
| 34 | MYGN | Myriad Genetics Inc | +0.4% | NEW | New buy |
| 35 | PLRX | Pliant Therapeutics Inc | +0.4% | NEW | New buy |
| 36 | MLTX | Moonlake Immunotherapeutics | +0.3% | — | Unchanged |
| 37 | 430 | Terns Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 38 | BRKR | Bruker CORP | +0.3% | +3.85% | Add |
| 39 | NTLA | Intellia Therapeutics Inc | +0.2% | NEW | New buy |
| 40 | QURE | uniQure N.V. | +0.2% | NEW | New buy |
| 41 | SANA | Sana Biotechnology Inc | +0.2% | +50.00% | Add |
| 42 | GEHC | GE Healthcare Technology | +0.2% | NEW | New buy |
| 43 | STAA | Staar Surgical Co | +0.2% | NEW | New buy |
| 44 | NRIX | Nurix Therapeutics Inc | +0.2% | +33.33% | Add |
| 45 | TNGX | Tango Therapeutics Inc | +0.2% | NEW | New buy |
| 46 | QDEL | Quidelortho CORP | +0.2% | -16.67% | Trim |
| 47 | RZLT | Rezolute Inc | +0.1% | NEW | New buy |
| 48 | LLY | Eli Lilly & Co | +0.1% | — | Unchanged |
| 49 | FATE | Fate Therapeutics Inc | +0.1% | +14.71% | Add |
| 50 | KYTX | Kyverna Therapeutics Inc | +0.1% | NEW | New buy |
According to official SEC Form 13F filings, Integral Health Asset Management, LLC reported a total U.S. public equity portfolio value of $2.5B across 66 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, THC, BSX) accounted for 12.4% of total reported equity market value during Q3 2024.
Top New Position Initiated
INSP
市值: $33.8M
Top Position Liquidated / Trimmed
ELV
前期市值: $43.3M
During Q3 2024, Integral Health Asset Management, LLC's top holdings by market value included INSM (11.9%)、THC (9.9%)、BSX (5.2%). The largest single position, INSM, represented 11.9% of total portfolio value.
In Q3 2024, Integral Health Asset Management, LLC made 93 total portfolio adjustments, initiating 31 new buys, adding to 13 positions, trimming 15 holdings, and fully liquidating 34 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.